Oak Ridge Investments LLC Sells 728 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Oak Ridge Investments LLC lessened its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,622 shares of the biopharmaceutical company’s stock after selling 728 shares during the quarter. Oak Ridge Investments LLC’s holdings in Ultragenyx Pharmaceutical were worth $1,034,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $28,000. nVerses Capital LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $33,000. UMB Bank n.a. raised its stake in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 352 shares in the last quarter. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $56,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Ultragenyx Pharmaceutical by 67.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 1,339 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $50.99 on Friday. The company’s fifty day moving average price is $55.92 and its 200 day moving average price is $47.82. Ultragenyx Pharmaceutical Inc. has a 1 year low of $32.83 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The firm had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. During the same period in the prior year, the firm posted ($2.25) earnings per share. The firm’s quarterly revenue was up 35.7% compared to the same quarter last year. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wedbush upped their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. TD Cowen upped their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 22nd. Finally, Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $85.08.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the transaction, the chief executive officer now directly owns 2,243,985 shares of the company’s stock, valued at $112,580,727.45. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,556 shares of company stock valued at $2,519,367 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.